BPC-157 for Muscle and Tendon Healing: What Science Actually Shows vs. What Athletes Believe | Research

The takeaway

BPC-157 shows robust regenerative effects in animal studies through multiple healing pathways, but only three small human pilot studies exist — making it investigational despite widespread athlete use.

Only 3 human studies
Despite decades of animal research and widespread athlete use, BPC-157 has only been tested in three small human pilot studies

What the researchers found

BPC-157 activates several key healing pathways in animal models: VEGFR2 and nitric oxide synthesis via the Akt-eNOS axis (promoting blood vessel growth), ERK1/2 signaling (facilitating tissue repair), fibroblast activation, and anti-inflammatory effects. These mechanisms are particularly relevant for poorly vascularized tissues like tendons and myotendinous junctions, which heal slowly.

However, the review found a stark gap between preclinical promise and clinical evidence. Only three small pilot studies have examined BPC-157 in humans: for knee pain (intraarticular), interstitial cystitis, and IV safety/pharmacokinetics. No adverse effects were reported in any human study, but none were powered to assess efficacy. The review concludes that BPC-157 should be considered investigational until well-designed clinical trials are completed.

Why it matters

BPC-157 has become one of the most popular peptides among athletes and wellness seekers, widely available through unregulated sources despite having almost no human clinical data. This 2025 review from a musculoskeletal medicine journal provides the most current, balanced assessment — acknowledging the robust preclinical evidence while clearly stating that human data is minimal. It directly calls for rigorous clinical trials, reflecting the growing tension between public demand and scientific evidence.

The numbers in context

Only 3 human pilot studies exist · mechanisms: VEGFR2, Akt-eNOS, ERK1/2 · 0 adverse events reported in humans · numerous positive animal models · FDA regulatory controversy noted

How the study worked

Scoping review evaluating the molecular mechanisms, therapeutic potential, and safety profile of BPC-157 for musculoskeletal applications. The authors assessed the breadth and quality of both preclinical (animal) and clinical (human) data, with particular attention to mechanism of action pathways and regulatory status.

Who was studied

Not applicable (scoping review covering preclinical and limited clinical data)

What this study cannot tell us

The review is narrative/scoping rather than systematic, meaning the search strategy and inclusion criteria may not be as rigorous as a full systematic review. The field itself is limited by the dominance of a single research group (Sikiric et al.) in the preclinical literature. The three human studies are all small pilots without control groups. The regulatory landscape for BPC-157 is complex and varies by jurisdiction, adding uncertainty about product quality from non-pharmaceutical sources.

How to read the evidence

This is a scoping review published in a peer-reviewed musculoskeletal medicine journal that provides a balanced assessment. The 'Moderate' grade reflects the thoroughness of the review itself, while acknowledging that the underlying evidence base is heavily preclinical with minimal human data.

When this study was published

Published in 2025, this is the most current review of BPC-157 for musculoskeletal applications. It captures the latest regulatory developments and provides an up-to-date assessment of the evidence gap.

The bigger picture

BPC-157 represents a fascinating case study in the gap between preclinical promise and clinical reality. It may be the most-used peptide that has never been through a proper clinical trial. This 2025 review from a mainstream medical journal signals that the academic community is taking BPC-157 seriously enough to call for rigorous human trials — a significant shift from the dismissive stance some have taken. If clinical trials confirm even a fraction of the animal data, BPC-157 could become an important tool in sports medicine and orthopedics.

Questions still open

Why haven't large clinical trials of BPC-157 been conducted despite decades of preclinical data?
What quality and purity issues exist with BPC-157 obtained from unregulated sources?
Could BPC-157 accelerate tendon healing enough to meaningfully change recovery timelines for athletes?

Common questions

How does BPC-157 help tendons and muscles heal?

BPC-157 appears to activate multiple healing pathways simultaneously. It promotes the growth of new blood vessels (angiogenesis) through VEGFR2 signaling, stimulates fibroblasts (the cells that build connective tissue), enhances nitric oxide production to improve blood flow, and reduces inflammation. These effects are particularly valuable for tendons and myotendinous junctions, which naturally have poor blood supply and heal slowly.

If there's so much animal data, why isn't BPC-157 approved?

Several factors: most preclinical studies come from a single research group, the peptide's extremely broad claimed effects raise skepticism in the medical community, and no pharmaceutical company has invested in the expensive clinical trials needed for FDA approval. The regulatory status is also complicated — the FDA has issued warnings about BPC-157 products sold as supplements. This review explicitly calls for well-designed human trials to bridge the evidence gap.

Read the original research

Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing.

Current reviews in musculoskeletal medicine, 18(12), 611-619

View on PubMed ↗Publisher’s paper ↗

Citation

McGuire, Flynn P; Martinez, Riley; Lenz, Annika; Skinner, Lee; Cushman, Daniel M. (2025). Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing.. Current reviews in musculoskeletal medicine, 18(12), 611-619. https://doi.org/10.1007/s12178-025-09990-7